TTThérèse Rachell Theodoro

Thérèse Rachell Theodoro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thérèse Rachell Theodoro has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immunoexpression of stem cell markers CD44, CD133, ALDH1-2, and LGR5 in colorectal carcinoma and their association with clinicopathological tumor characteristics

    by Karine Corcione Turke, Cinthia dos Santos, Carla Pagliari, Giovanna Maria Gimenez Testa, Thérèse Rachell Theodoro, Bianca Bianco, Jaques Waisberg

    To investigate the association of CD44, CD133, ALDH1-2, and LGR5 expression with clinicopathological tumor variables. Twenty-eight adult patients with colorectal carcinoma who underwent curative surgery were included in the study. Paraffin-embedded samples were subjected to immunohistochemical staining with anti-CD44, anti-CD133, anti-ADLH1-2, and anti-LGR5 antibodies, and the results were compared with the patients' clinicopathological variables. P-values 60 years of age, in the rectum and right colon, and in the presence of lymph node involvement. CD44 protein expression was increased in tumors of the left colon. Increased tissue levels of ALDH1-2 and LGR5 were related to increased aggressiveness of colorectal carcinoma.


  • Open Access

    MicroRNA signatures associated with radioiodine refractoriness and tumor dedifferentiation in metastatic papillary thyroid carcinoma

    by Ana Kober Leite, Kelly Cristina Saito, Thérèse Rachell Theodoro, Fátima Solange Pasini, Venâncio Avancini Ferreira Alves, Luiz Paulo Kowalski, Maria Aparecida Silva Pinhal, Gilberto Mendes Junior Menderico, Edna Teruko Kimura, Leandro Luongo Matos

    Purpose: Radioiodine (RAI) refractoriness and tumor dedifferentiation are major contributors to poor outcomes in metastatic papillary thyroid carcinoma (PTC). microRNAs (miRNAs) are promising biomarkers to identify these aggressive phenotypes. This study aimed to characterize miRNAs expression profiles associated with RAI refractoriness and dedifferentiation. Methods: From a cohort of 108 metastatic PTC patients, 24 cases with available formalin-fixed paraffin-embedded tissue were selected for molecular analysis, including 17 patients who died from disease progression and 7 long-term survivors with stable disease. Total RNA was extracted and analyzed by qPCR. miRNAs with differential expression ( P < 0.10) in univariate analysis were included in multivariate linear regression models. Diagnostic performance was assessed using ROC curve analysis and hierarchical clustering. Results: The cohort had a mean age of 55.2 years and was predominantly male (66.7%). RAI-refractory disease was present in 63.2% of evaluable cases, and dedifferentiation in 33.3%. In multivariate analysis, lower expression of miR-200c-3p was independently associated with RAI refractoriness ( P = 0.005). For tumor dedifferentiation, higher expression of let-7i-5p ( P < 0.001) and miR-19b-3p ( P < 0.001), and lower expression of miR-31-5p ( P = 0.004) and let-7e-5p ( P = 0.036), were independently associated. ROC curve analysis demonstrated high diagnostic accuracy for miR-200c-3p (AUC = 0.929) and let-7i-5p (AUC = 0.958) for, respectively, RAI refractoriness and tumor dedifferentiation. Heatmap analysis revealed clear segregation of phenotypic groups based on miRNA expression. Conclusions: Distinct miRNAs signatures are associated with RAI refractoriness and tumor dedifferentiation in metastatic PTC. These findings support their potential as prognostic biomarkers and may guide future therapeutic stratification.

  • Open Access

    MicroRNA expression signatures associated with metastatic progression in papillary thyroid carcinoma

    by Vinicius Ferreira Capelli Capelli, Ana Kober Leite, Kelly Cristina Saito, Thérèse Rachell Theodoro, Fátima Solange Pasini, Venâncio Avancini Ferreira Alves, Luiz Paulo Kowalski, Maria Aparecida Silva Pinhal, Edna Teruko Kimura, Leandro Luongo Matos

    The objective of this study is to compare the miRNA expression profiles of primary tumors and matched metastatic lesions from patients who died due to progression of metastatic PTC. We conducted an exploratory study of patients with PTC who died from disease progression and had tissue samples available from both primary tumors and distant metastases. Total RNA was extracted and analyzed to assess the expression of 64 preselected miRNAs. Expression data were normalized using endogenous controls (let-7g-5p and miR-181a-5p), and differential expression was calculated using the 2-∆Ct method. Those miRNAs detected in < 70% of samples or with cycle threshold (Ct) > 36 were excluded. Univariate analyses were performed using paired tests, and multivariate results were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) method. Out of 3,555 patients treated for PTC between 1986 and 2015, eight patients were included. Univariate analysis identified five miRNAs differentially expressed in metastatic lesions: let-7e-5p, miR-10b-5p, miR-30e-3p, miR-423-5p, and miR-483-3p. After multivariate adjustment, miR-10b-5p and miR-30e-3p remained independently overexpressed in metastatic tissues. This study is one of the first to demonstrate distinct miRNA expression profiles in metastatic versus primary tumors in fatal PTC cases. The identified miRNAs are known to regulate processes such as cell migration, invasion, and apoptosis in other cancers, suggesting their potential contribution to PTC metastasis.

  • Open Access

    Expression profiles of miR-23a andmiR-146a in the peripheral blood of women with premature ovarian insufficiency

    by Thérèse Rachell Theodoro, Rafael Bitelman Barreiro, Isabella Verdi Cunha, Bianca Bianco, Caio Parente Barbosa, Denise Maria Christofolini

    INTRODUCTION Premature ovarian insufficiency (POI) is a clinical syndrome characterized by oligo/amenorrhea observed in women before the age of 40 years, lasting at least 4 months, with elevated follicle-stimulating hormone (FSH) levels.() Its diagnosis is confirmed by two serum measurements conducted at least 1 month apart that show high FSH levels (>25IU/L) and low estradiol levels.() The condition is caused by varying factors, including genetic, immunological, or metabolic factors; iatrogenic intervention; and environmental toxins. The reason is idiopathic in 90%


  • Open Access

    PRESENÇA DO PAPILOMAVIRUS HUMANO TIPO 16 E EXPRESSÃO GÊNICA DA PROTEÍNA P16INK4A E ONCOPROTEÍNA E7 NO CARCINOMA COLORRETAL

    by Olavo Magalhães Picanço-Junior, Thérèse Rachell Theodoro, Paulo José de Brito Silva Albuquerque, Rodrigo Nascimento Pinheiro, Jaques Waisberg

    RESUMO - INTRODUÇÃO: O papilomavírus humano (HPV) é agente das doenças sexualmente transmissíveis de maior prevalência no mundo que estão associadas ao câncer do colo do útero e canal anal. A ação do HPV na carcinogênese colorretal não está ainda estabelecida. OBJETIVO: Estudar a eventual correlação entre a presença do HPV tipo 16 e a expressão gênica da proteína p16INK4a e da oncoproteína E7 de HPV e de seus níveis no tecido do carcinoma colorretal. METODOS: Estudo retrospectivo caso-controle de 79 doentes com carcinoma colorretal divididos em dois grupos: HPV presente e HPV ausente. Foi realizada reação em cadeia da polimerase (PCR), além da hibridização do tipo dot blot para o HPV 16 e o HPV 18 Amostras do tecido colorretal também foram submetidas ao estudo imuno-histoquimico para avaliar o nível tecidual das proteínas E7 e p16INK4a. RESULTADOS: O HPV foi identificado em 36 (45,6%) casos. Não houve diferença significante entre os grupos quanto ao sexo (p=0,056), idade (p=0,1), localização cólica e/ou retal (0,098) e presença do HPV. A expressão gênica da oncoproteína E7 de HPV estava presente em 3,12% dos casos (p=0,9) e a expressão da proteína p16INK4a foi observada em 46,3% (p=0,27) dos indivíduos com detecção do HPV. CONCLUSÃO: A expressão gênica e os níveis teciduais da oncoproteína E7 e da proteína p16INK4a encontrados nos pacientes positivos para o HPV sugerem a ausência de atividade oncogênica do HPV tipo 16 no carcinoma colorretal.


  • Cancer-associated fibroblast regulation by microRNAs promotes invasion of oral squamous cell carcinoma

    by Leandro Luongo Matos, Gilberto Mendes Menderico Junior, Thérèse Rachell Theodoro, Fatima Solange Pasini, Marina de Menezes Ishikawa, Andrômeda Aryane Bomtempo Ribeiro, Evandro Sobroza de Mello, Maria Aparecida da Silva Pinhal, Raquel Ajub Moyses, Marco Aurelio Vamondes Kulcsar, et al.


  • Molecular alterations of human lumbar yellow ligament related to the process of intervertebral disk degeneration and stenosis

    by Delio E. Martins, Marcelo Wajchenberg, Juliana M. Veridiano, Thérèse R. Theodoro, Olga M. S. Toledo, Maria A. S. Pinhal

    The objective of this study was to analyze the layers of yellow ligament in lumbar canal stenosis and disk herniation.


  • Open Access

    Expression of heparanase in basal cell carcinoma and squamous cell carcinoma

    by Maria Aparecida Silva Pinhal, Maria Carolina Leal Almeida, Alessandra Scorse Costa, Thérèse Rachell Theodoro, Rodrigo Lorenzetti Serrano, Carlos D'APparecida Santos Machado Filho

    Heparanase is an enzyme that cleaves heparan sulfate chains. Oligosaccharides generated by heparanase induce tumor progression. Basal cell carcinoma and squamous cell carcinoma comprise types of nonmelanoma skin cancer. Evaluate the glycosaminoglycans profile and expression of heparanase in two human cell lines established in culture, immortalized skin keratinocyte (HaCaT) and squamous cell carcinoma (A431) and also investigate the expression of heparanase in basal cell carcinoma, squamous cell carcinoma and eyelid skin of individuals not affected by the disease (control). Glycosaminoglycans were quantified by electrophoresis and indirect ELISA method. The heparanase expression was analyzed by quantitative RT-PCR (qRTPCR). The A431 strain showed significant increase in the sulfated glycosaminoglycans, increased heparanase expression and decreased hyaluronic acid, comparing to the HaCaT lineage. The mRNA expression of heparanase was significantly higher in Basal cell carcinoma and squamous cell carcinoma compared with control skin samples. It was also observed increased heparanase expression in squamous cell carcinoma compared to the Basal cell carcinoma. The glycosaminoglycans profile, as well as heparanase expression are different between HaCaT and A431 cell lines. The increased expression of heparanase in Basal cell carcinoma and squamous cell carcinoma suggests that this enzyme could be a marker for the diagnosis of such types of non-melanoma cancers, and may be useful as a target molecule for future alternative treatment.